Home Page > Research areas
LU15: Adding GCSF (filgrastim) to chemotherapy to try and increase the dose intensity of chemotherapy given to patients with small cell lung cancer.
Can chemotherapy drugs be given at 2-weekly intervals (rather than 3-weekly) if drugs that boost the blood count are given at the same time?
  • What was this study about?

    Although chemotherapy kills cancer cells, it also kills normal blood cells. As a result chemotherapy can only be given every 3 weeks, as it takes this long for the normal blood cells to recover. However, the cancer cells may also grow in the 3 weeks between chemotherapy cycles. Researchers thought that a drug called G-CSF might help the normal blood cells to recover more quickly, and so enable people to have chemotherapy every 2 weeks. So they designed a trial to see if this was the case. Two drug companies made G-CSF. The LU15 trial looked at the G-CSF made by one company (Amgen) and LU14 looked at the G-CSF made by another company.
  • Who took part?

    32 people took part.
  • When was it carried out?

    The study was carried out in 1992 and 1993, and a report was published in 1995.
  • Where did it take place?

  • Who funded the study?

    The Medical Research Council, and the drug company Amgen donated the GCSF
  • Contact details

  • What difference did this study make?

    This new treatment was very effective. Most patients had at least the first 4 cycles of chemotherapy at 2-week intervals, although some patients experienced some serious side-effects.

    It showed this policy was feasible and led to a large randomised trial comparing standard (3-weekly) chemotherapy and intensive (2-weekly) chemotherapy – the LU19 trial.
  • Further Information


    Type of study:Non-randomised trial
    Status:Closed